A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

NCT02260674 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

114

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: JNJ-54861911, 10 milligram (mg)
DRUG: JNJ-54861911, 50 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC